Pharming Group N.V.

NASDAQ:PHAR

Biotechnology

Healthcare
$12.48 +2.19%

+$0.28 today

Market cap
$882.43M
Beta
0.10
P/E (TTM)
77.0
EPS (TTM)
$0.02
52W Low $9.54High $21.34

Volume 0.01M

Average 0.01M

PHAR Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Pharming Group N.V.NASDAQ: PHAR

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity rises 24.9% from a year ago

Total equity stood at $268.96M at the end of Q1 FY2026, up 24.9% from a year earlier and down 2.9% from the prior quarter. Over 3 fiscal years it compounded at +10.6% a year.

Context

  • Total equity amounted to 55.0% of total assets at the end of Q1 FY2026, up 1.6 pp from a year earlier.
  • Total equity increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +24.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$268.96M-2.9% QoQ
Last fiscal yearDec 2025
$277.02M+21.0% YoY
Year agoMar 2025
$215.29M+24.9% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+24.9%——
1 year+21.0%——
3-year CAGR+10.6%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
277.02M USD
Year-over-year change
+21.0%
4-year CAGR
+6.1%

Total Equity vs competitors

How PHAR compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +24.9% is the 3rd highest of 10, against a peer median of -15.1%.
  • Total equity amounts to 55.0% of total assets for PHAR, versus a peer median of 81.4%.
PHAR Competitors
Total Equity for PHAR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BMRNBioMarin Pharmaceutical Inc.Sep 2026$6.26T USD+103190.9%+9.8%54.1%
NTLAIntellia Therapeutics, Inc.Mar 2026$620.94M USD-20.4%-18.4%81.8%
STOKStoke Therapeutics, Inc.Mar 2026$394.88M USD+12.8%+24.0%89.1%
IONSIonis Pharmaceuticals, Inc.Sep 2026$393.64M USD-36.3%-5.1%13.5%
PHARPharming Group N.V.Mar 2026$268.96M USD+24.9%+10.6%55.0%
PHVSPharvaris N.V.Sep 2026€264.97M EUR-15.1%+22.0%89.8%
RCKTRocket Pharmaceuticals, Inc.Mar 2026$238.04M USD-42.2%-17.3%83.4%
SLNSilence Therapeutics plcMar 2026$49.4M USD+143.8%+41.3%42.9%
PRQRProQR Therapeutics N.V.Mar 2026€37.64M EUR-55.9%-9.5%38.0%
BCRXBioCryst Pharmaceuticals, Inc.Jun 2026-$454.29M USD-7.8%—81.4%
Peer median (excluding PHAR) —-15.1%+2.3%81.4%

Competitors are the stored peer set for PHAR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents217.59M207.34M61.74M56.89M146.02M
Short-term Investments00151.68M116.96M33.79M
Net Receivables31.28M25.33M42.62M51.95M54.69M
Inventory30.96M42.33M56.76M57.7M64.88M
Other Current Assets257.35K213K001K
Total Current Assets282.8M277.5M316.34M288.32M299.38M
Property, Plant & Equipment (Net)37.6M39.15M33.47M24.12M23.96M
Goodwill0000135.5M
Intangible Assets95.04M75.12M71.27M63.21M0
Long-term Investments9.81M9.73M10.4M4.38M9.87M
Tax Assets24.05M22.97M29.76M31.63M31.01M
Other Non-current Assets1.14M1.33M1.62M2.52M93.98K
Total Non-current Assets167.64M148.3M146.51M125.86M200.43M
Total Assets450.44M425.8M462.85M414.18M499.81M
Account Payables8.62M8.75M16.02M10.46M105.87M
Short-term Debt2.13M1.77M1.82M4.4M5.34M
Tax Payables1.71M2.1M6.23M3.4M0
Deferred Revenue00000
Other Current Liabilities0003.4M1.22M
Total Current Liabilities53.02M59.7M77.97M76.42M115.79M
Long-term Debt157.59M131.62M136.6M80.93M92.72M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities187.06K0000
Total Non-current Liabilities178.7M161.46M166.11M108.85M107.07M
Total Liabilities231.73M221.16M244.07M185.27M222.79M
Common Stock8.42M7.51M7.67M8.04M8.01M
Retained Earnings(309.69M)(256.43M)(265.26M)(285.27M)(272.9M)
Accumulated OCI3.85M(8.74M)(2.06M)(216.42K)0
Other Stockholders Equity000028.81M
Minority Interest00000
Total Equity218.71M204.64M218.78M228.91M277.02M
Total Debt183.39M166.69M171.55M116.3M115.78M
Net Debt(34.2M)(40.65M)109.8M59.41M(30.25M)

Pharming Group N.V.

NASDAQ:PHAR

Intrinsic Alpha fair value

Locked

Current Price

$12.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.